Table of Contents Table of Contents
Previous Page  265 / 812 Next Page
Information
Show Menu
Previous Page 265 / 812 Next Page
Page Background

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S116–S348

S261

Introduction

The influence of the immune deregulation on the

risk and psychopathology of schizophrenia is increasingly recog-

nized in the literature.

Aim

To assess the association between serum IL-1RA on

schizophrenia psychopathology.

Methods

We recruited 88 schizophrenia patients (38 males

and 49 females, mean age 38.12

±

12.67 years) and 88 healthy

adult control subjects (68 males, 20 females, mean age

40.63

±

7.99 years). Lifetime psychopathology was evaluated using

Operational Criteria for Psychotic Illness (OPCRIT) checklist, while

current psychopathology was assessed using Positive and Negative

Syndrome Scale (PANSS). Serum samples were stored in aliquots at

–80

C. Serum levels of IL1-RA were measured using Immunoassay

(ELISA).

Results

There were statistically significant differences

between schizophrenia patients and healthy controls

(median

±

interquartile range: 350,81

±

227.04 and 888.74

±

762.63, respectively [pg/ml]) (

U

Mann–Whitney test,

Z

= –7.99,

P

< 0.0001). There were no differences in serum IL1-RA levels

between male and female among patients with schizophrenia

(

U

Mann–Whitney test,

Z

= –0.22,

P

= 0.82) nor among healthy

control subjects (

U

Mann–Whitney test,

Z

= –0.17,

P

= 0.86).

Among schizophrenia patients, there was a trend-level association

between IL-1RA serum level with negative symptoms (Spearman

correlation coefficient,

r

= –0.23,

P

= 0.056), positive symptoms

(Spearman correlation coefficient

r

= –0.22,

P

= 0.066), and on a

statistically significant level with general symptoms (Spearman

correlation coefficient

r

= –0.28,

P

= 0.018).

Conclusion

SerumIL1-RA level is higher in schizophrenia patients

in comparison to healthy controls and it is associated with

schizophrenia psychopathology.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.537

EW420

The prevalence of voltage-gated

potassium channel (VGKC) and

glutamic acid decarboxylase (GAD)

autoantibodies in psychotic disorders:

A systematic review and meta-analysis

R. Grain

1 ,

, J. Lally

2

, A. Lemince

3

, B. Stubbs

4

, F. Gaughran

5

1

London, United Kingdom

2

Institute of Psychiatry, Psychology and Neuroscience IOPPN,

Psychosis Studies, London, United Kingdom

3

South London and Maudsley NHS Trust, South London and

Maudsley NHS Trust, London, United Kingdom

4

South London and Maudlsey NHS Trust, Physiotherapy, London,

United Kingdom

5

Institute of Psychiatry, Psychology and Neuroscience, Psychosis

Studies, London, United Kingdom

Corresponding author.

Introduction

Antibodies to the voltage-gated potassium channel

(VGKC) complex and glutamic acid decarboxylase (GAD) have been

reported in some cases of psychosis. We conducted the first sys-

tematic review on VGKC and GAD, and meta-analysis on GAD, to

investigate their prevalence in people with psychosis.

Objectives

The objective was to examine the available evidence

to determine the prevalence of serum VGKC and GAD antibody

positivity in psychosis.

Aims

To search the available literature for data indicating the

prevalence of these antibodies in psychosis. If data were sufficient,

we anticipated conducting a meta-analysis.

Methods

Two authors searched major electronic databases for

studies reporting the prevalence of VGKC and GAD65 antibody

seropositivity in psychotic disorders. We then conducted a random

effects analysiswith ComprehensiveMeta-Analysis software (CMA,

Version 3).

Results

Only three studies presenting prevalence rates of VGKC

sero-positivity in psychosis could be identified, with an overall

prevalence of 0.5% (1/196) with to 0% in healthy controls (0/50).

Meta-analysis established the pooled prevalence of GAD65 autoan-

tibodies was 8.67% (95% CI 3.9–17.80%,

I

2

= 75%, 8 studies) in

psychotic disorders. People with psychosis were more likely to

have GAD65 antibodies than controls (OR 3.14 95% CI 1.55–6.37%,

P

= 0.001, 7 studies,

I

2

= 0%).

Conclusions

Rates of VGKC antibody positivity appear to be low

in psychosis, although there is a lack of published evidence. The

prevalence of GAD65 antibodies is higher but available studies did

not control for the presence of T1 diabetes, a condition in which

GAD65 antibodies are also found.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.538

EW421

Adverse childhood experiences and

later in life depression as risk factors

for cancer incidence and mortality.

A nationally representative,

prospective longitudinal study

M.V. Hansen

Aarhus, Denmark

Introduction

Adverse childhood experiences (ACEs) have shown

to influence the risk of various chronic diseases alone, and in combi-

nation with depression later in life. To date, only little research has

examined the relationship, and findings have been inconsistent.

Objective

To conduct a nationwide prospective study on ACEs

and the risk of cancer.

Aims

– Examine the relationship between ACE and a range of

cancer types;

– to test for a linear dose-response relationship;

– to investigate differences in the effects of the specific ACE on the

risk of cancer;

– to determine if there are any sex differences as well as windows

of vulnerability;

– to examine if later in life occurrence of depression influence the

risk of cancer in combination with ACE.

Methods

A prospective population-based study including

approximately 1.1 mio individuals was conducted using linked

Danish registries that hold data on objective measures of ACEs and

cancer incidences. Survival analyses were used to estimate relative

risk of cancer among those with ACE and depression, compared to

those without, while adjusting for relevant confounders.

Results

This study will provide results on the relative risk of can-

cer after exposure to ACE compared to those without, as well as

information on the combination of ACE and depression, sex differ-

ences, effect of timing and dose-response analyses.

Conclusion

This preliminary study will help to further advance

our understanding on how ACES influence the risk of serious

chronic diseases later in life, and the findings may contribute to

understanding the etiology of cancer.

Disclosure of interest

The author has not supplied his/her decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.539